Evidence map›Paper›PMID 39968379›Full record

ArticleBioinformatics advances2025

Accurate, comprehensive database of group I introns and their homing endonucleases.

Lara Sellés Vidal, Tomoya Noma, Yohei Yokobayashi

Abstract read
In one paragraph

Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A prevalent huge phage clade in human and animal gut microbiomes.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lara Sellés VidalNucleic Acid Chemistry and Engineering Unit, Okinawa Institute of Science and Technology Graduate University, Onna, Okinawa 9040495, Japan.ORCID https://orcid.org/0000-0003-2537-6824
Tomoya NomaNucleic Acid Chemistry and Engineering Unit, Okinawa Institute of Science and Technology Graduate University, Onna, Okinawa 9040495, Japan.
Yohei YokobayashiNucleic Acid Chemistry and Engineering Unit, Okinawa Institute of Science and Technology Graduate University, Onna, Okinawa 9040495, Japan.ORCID https://orcid.org/0000-0002-2417-1934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Group I introns are one of the most widely studied ribozymes. Since their initial discovery, a large number of them have been identified experimentally or computationally. However, no comprehensive and unified database that provides group I intron sequences with precise boundaries and structural information is available. Results: We created a new database of group I intron sequences with reliable exon-intron boundaries. The database offers additional data for each sequence, such as containing GenBank entry, its position within the associated entry, the subtype of each intron and putative homing endonucleases. Secondary structure predictions and base-pairing probability matrixes are also provided for each sequence. The resource is expected to facilitate large-scale studies of group I introns, as well as engineering for novel applications. Availability and implementation: The database, as well as the code to generate it and a GUI to facilitate its exploration, are available at https://github.com/LaraSellesVidal/Group1IntronDatabase. The source code for the GUI implementation is available at https://github.com/LaraSellesVidal/OnlineGroup1IntronDatabase. The database can also be accessed online at https://online-group-1-intron-database.onrender.com. Base-pairing probability matrixes are available separately at https://www.ebi.ac.uk/biostudies/studies/S-BSST1399.

Identifiers

PMID39968379
PMCPMC11835236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.